Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide profiling of H3K27ac (ChIP-seq) in IMR90 cells

ABSTRACT: Genome-wide profiling of H3K27ac (ChIP-seq) in IMR90 cells

PROVIDER: PRJEB18688 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1766286.fastq.gz	Fastqsanger.gz
	ERR1766287.fastq.gz	Fastqsanger.gz
	ERR1766288.fastq.gz	Fastqsanger.gz
	ERR1766289.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Genome-wide profiling of H3K27ac (ChIP-seq) in IMR90 cells

Project description:To determine the genome-wide pattern of H3K27ac in IMR90 (ATCC CCL-186) cells we performed ChIP-seq upon hormone treatment (1.5 h, 1 M dexamethasone).

2018-04-12 | E-MTAB-5355 | biostudies-arrayexpress

ChIP-seq for CTCF, H3K4me3 and H3K27ac following CTCF RNAi in LNCaP cells and IMR90 cells

Project description:ChIP-seq for CTCF, H3K4me3 and H3K27ac following CTCF RNAi in LNCaP cells and IMR90 cells

| PRJNA518745 | ENA

Genome-wide Profiling of H3K27ac binding in human cancer cell lines

Project description:Upregulation of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) and its associated histone H3 lysine 27 (H3K27) trimethylation frequently occur in human cancer, yet both preclinical and clinical evidence suggested the very limited benefit of EZH2-targeted therapies. This study investigated the underlying mechanisms from a perspective of EZH2 inhibition-caused histone modification crosstalk. A mass spectrometry approach enabled us discovering the alteration of global histone modifications responding to EZH2 inhibition. Feedback upregulation of H3K27 acetylation (H3K27ac) level is closely associated with limited drug response to EZH2 inhibition across multiple cancer types. H3K27ac alteration caused transcriptional activation of oncoproteins confers drug resistant to EZH2 inhibition. Here we used ChIP-Seq analysis to identify the alteration of genome-wide H3K27ac bingding sites with EZH2 inhibitor treatment in human cancer cell lines.

2018-09-26 | GSE119086 | GEO

Genome-wide maps of PRDM16 binding sites and histone modifications [H3K27Ac ChIP-Seq]

Project description:Genome-wide maps of PRDM16 binding sites and histone modifications [H3K27Ac ChIP-Seq]

| PRJNA437764 | ENA

Chromatin dynamics of p53 binding sites in IMR90

Project description:We report the chromatin modification dynamics at p53 binding sites upon treatment with DMSO or nutlin3-a (5uM) in IMR90 human lung fibroblasts using ChIP-seq and RNA-seq analyses. We assessed the genomewide changes in H3, H3K4me3, H3K4me2, H3K4me1, H3K27ac, H4K16ac, RNA polymerase II, and p53 in response to p53 activation.

2014-11-12 | GSE58740 | GEO

Genome-wide maps of H3K27ac localization in HUVECs

Project description:H3K27Ac is one of the expressed enhancer markers in endothelial cells, but its genomic localization is unknown. This time, we established a new antibody for H3K27ac, and performed ChIP-seq to identify H3K27ac binding site in whole genome manner under hypoxia. We used chromatin immunoprecipitation with deep sequencing (ChIP-seq) of HUVECs treated with or without hypoxia (1%O2) for 24hours, then H3K27ac binding regions were identified. Normoxia was used as a control condition. HUVECs were used within the first 6 passages.

2013-01-01 | E-GEOD-38555 | biostudies-arrayexpress

Glucocorticoid receptor profiling in IMR90, K562 and U2OS (ChIP-exo)

Project description:Glucocorticoid receptor profiling in IMR90, K562 and U2OS (ChIP-exo)

| PRJEB7365 | ENA

Glucocorticoid receptor profiling in IMR90,K562 and U2OS (ChIP-seq)

Project description:Glucocorticoid receptor profiling in IMR90,K562 and U2OS (ChIP-seq)

| PRJEB7372 | ENA

Modeling transcriptional cis-regulation with a library of genome-wide histone H3K27ac profiles

Project description:We describe, MARGE, Model-based Analysis of the Regulation of Gene Expression, a robust methodology that leverages a large library of genome-wide H3K27ac ChIP-seq profiles to predict key regulated genes and cis-regulatory regions in human or mouse. MARGE adopts a gene centric approach to define a regulatory potential that summarizes the aggregate activity of multiple cis-regulatory elements on each gene. This model is effective in describing cis-regulatory activity and, unlike the super-enhancer based approach, is highly predictive of gene expression changes in response to BET-bromodomain inhibitors. We show that linear combinations of H3K27ac defined regulatory potentials, selected from an extensive database of published H3K27ac profiles, can accurately model diverse gene sets derived from differential gene expression experiments. In addition, we demonstrate a novel semi-supervised learning approach for identifying transcription factor binding sites associated with the set of transcription factors that regulate the gene set. MARGE leverages published H3K27ac ChIP-seq data to enhance the interpretation of newly generated H3K27ac ChIP-seq profiles. MARGE can also be used to analyze gene expression studies, without the production of matched H3K27ac ChIP-seq data. Identifying genomic profiles of histone modification H3K27ac in LNCaP-abl cell line after siRNA knock down of a series of gene factors.

2016-05-16 | E-GEOD-72467 | biostudies-arrayexpress

ChIP-Seq data from IMR90 Control and IMR90 HRAS-G12V using an H3K79me3 antibody

Project description:ChIP-Seq data from IMR90 Control and IMR90 HRAS-G12V using an H3K79me3 antibody

| PRJNA658469 | ENA